Skip to contentB
Bio-Rad Laboratories, Inc.
B
BIOBio-Rad Laboratories, Inc. Q4 2022 · 10-K
Revenue$730.24M$730.24Mderived−0.3% vs Q4 2021 Net Income$827.70M$827.70MN/M vs Q4 2021 EPS Diluted$27.78$27.78N/M vs Q4 2021 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Bio-Rad Laboratories, Inc. · CIK 12208 · Engraved from SEC EDGAR
−0.7%
Operating Incomederived$118,654,000+0.6% Operating Cash Flowderived$79,610,000−53.4% Free Cash Flowderived$44,797,000−60.9% Margins · derivedGross margin54.4%−0.2 pt vs Q4 2021
Operating margin16.2%+0.2 pt vs Q4 2021
Net margin113.3%+327.9 pt vs Q4 2021
ended Dec 31, 2022 · filed Feb 17, 2023 · 48 d after period end